The effect of sertraline on depression and associations with persistent depression in survivors of HIV-related cryptococcal meningitis
Open Access
- 26 February 2021
- journal article
- research article
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 6, 45
Abstract
Background: Depression is a risk factor for worse outcomes in persons living with HIV/AIDS and has a prevalence more than three times as high as in the general population. Despite this, there are few randomized studies of antidepressants in HIV-infected Africans. Methods: We enrolled 460 HIV-infected Africans with cryptococcal meningitis into a randomized clinical trial of adjunctive sertraline vs placebo (2015-2017). We defined depression using depression using a Center for Epidemiologic Studies Depression Scale (CES-D) score of >15, and severe depression as >26 at one and three months after meningitis diagnosis and initiation of treatment.We evaluated the relationship between sertraline and depression, as well as associations with persistent depression, at three months. Results: At one- and three-months post meningitis diagnosis, 62% (108/174) and 44% (74/169) of all subjects had depression (CES>15), respectively. At three months, sertraline-treated subjects had consistent risk for depression as placebo-treated subjects but were significantly less likely to have severe depression (CES>26) (OR 0.335; 95%CI, 0.130-0.865). Of those with depression at one month, sertraline-treated subjects were less likely than placebo-treated subjects to be depressed at three months (p=0.05). Sertraline was the only factor we found significant in predicting persistent depression at three months among those who had depression at one month. Conclusions: Depression is highly prevalent in HIV-infected persons who have survived cryptococcal meningitis. We found that sertraline is associated with a modest reduction in depression in those with depression at baseline and a significant decrease in severe depression.Keywords
Funding Information
- Medical Research Council (M007413/1)
- Wellcome Trust (210772)
- Grand Challenges Canada (S4-0296-01)
- National Institute of Mental Health (K23MH121220)
- National Institute of Neurological Disorders and Stroke (R01NS086312)
- National Institute of Allergy and Infectious Diseases (T32AI055433)
- Fogarty International Center (R25TW009345)
This publication has 21 references indexed in Scilit:
- Burden of Depression in Outpatient HIV-Infected adults in Sub-Saharan Africa; Systematic Review and Meta-analysisAIDS and Behavior, 2020
- Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trialThe Lancet Infectious Diseases, 2019
- Antidepressants for depression in adults with HIV infectionCochrane Database of Systematic Reviews, 2018
- Multimorbidity and depression: A systematic review and meta-analysisJournal of Affective Disorders, 2017
- Systematic Review of Interventions for Depression for People Living with HIV in AfricaAIDS and Behavior, 2017
- Exercise and mental health of people living with HIV: A systematic reviewChronic Illness, 2017
- Disparities in achieving and sustaining viral suppression among a large cohort of HIV-infected persons in care – Washington, DC*AIDS Care, 2016
- Factors That Affect Quality of Life among People Living with HIV Attending an Urban Clinic in Uganda: A Cohort StudyPLOS ONE, 2015
- Group psychotherapies for depression in persons with HIV: A systematic reviewIndian Journal of Psychiatry, 2013
- Depression underdiagnosis and the effects on quality of life in outpatients with HIV at a Nigerian university teaching hospitalAfrican Journal of AIDS Research, 2011